Statins in pregnancy

Current Opinion in Obstetrics and Gynecology

Volumn 25, Issue 6, 2013, Pages 433-440

  Morton, Suzanna ^a   Thangaratinam, Shakila ^a,b  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

congenital abnormality; foetus; pregnancy; statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABSENCE OF SIDE EFFECTS; ANENCEPHALUS; ANGIOMA; AORTA COARCTATION; BICUSPID AORTIC VALVE; BRAIN AQUEDUCT STENOSIS; CARDIOMEGALY; CLEFT LIP; CLEFT PALATE; CLUBFOOT; CONGENITAL MALFORMATION; DRUG SAFETY; DUODENUM ATRESIA; ESOPHAGUS ATRESIA; FETUS DEVELOPMENT; FETUS DISEASE; FETUS OUTCOME; FINGER MALFORMATION; GROWTH RETARDATION; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HEMANGIOMA; HIP MALFORMATION; HOLOPROSENCEPHALY; HUMAN; HYDROCEPHALUS; HYPOSPADIAS; INDUCED ABORTION; LIMB MALFORMATION; MATERNAL HYPERTENSION; META ANALYSIS; MICROCEPHALY; MICROTIA; NEURAL TUBE DEFECT; OMPHALOCELE; PATENT DUCTUS ARTERIOSUS; PATENT FORAMEN OVALE; POLYDACTYLY; PREECLAMPSIA; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PULMONARY ARTERY STENOSIS; PULMONARY HYPERTENSION; REVIEW; SPINAL DYSRAPHISM; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TERATOMA; URETER OBSTRUCTION; URETHRA OBSTRUCTION;

CONGENITAL ABNORMALITIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84888130525     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000026     Document Type: Review

References (29)

1. Kanagalingam MG, Forouhi NG, Greer IA, Sattar N. Changes in booking body mass index over a decade: retrospective analysis from a Glasgow Maternity Hospital. BJOG 2005; 112:1431-1433.
2. Andrade S, Raebel M, Brown J, et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf 2008; 17:240-247.
3. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38:90-96.
4. Eapen D, Valiani K, Reddy S, et al. Management of familial hypercholesterolaemia during pregnancy: case series and discussion. J Clin Lipidol 2012; 6:88-91.
5. Wang A, Rana S, Karumanchi SA. The role of angiogenic factors in its pathogenesis. Physiology 2009; 24:147-158.
6. National Institute for Health and Clinical Excellence. Diabetes in Pregnancy. 2008; CG63:12-13.
7. National Institute for Health and Clinical Excellence. Guidance on identification and management of familial hypercholesterolaemia. 2008; CG71:43.
8. Kusters DM, Lahsinoui H, van de Post JA, et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther 2012; 10:363-378.
9. Godfrey LM, Erramouspe J, Cleveland KW. Teratogenic risk of statins in pregnancy. Ann Pharmacother 2012; 46:1419-1424.
10. Lecarpentier E, Morel O, Fournier T, et al. Statins and pregnancy between supposed risks and theoretical benefits. Drugs 2012; 72:773-788.
11. Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolaemia: a harmful period for both mother and newborn? Curr Opin Lipidol 2009; 20:484-490.
12. Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: A systematic review. J Obstet Gynaecol Can 2007; 29:906-908.
13. Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG 2013; 120:463-471.
14. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 2008; 26:175-177.
15. McGrogan A, Snowball J, de Vries CS. Statins and pregnancy outcomes: a cohort study in the GPRD. Pharmacoepidemiol Drug Saf 2009; 18 (Suppl. 1): S75-S76; and personal communication for further details.
16. Freyssinges C, Ducroq M. Simvastatine et grossesse. Therapie 1996; 51:537-542.
17. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007; 64:496-509.
18. Petersen EE,Mitchell AA, Carey JC, et al. Maternal exposure to statins and risk for birth defects: a case series approach. Am J Med Genet A 2008; 146A:2701-2705.
19. Pollack PS, Shields E, Burnett DM, et al. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 2005; 73:888-896.
20. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004; 131A:287-298.
21. Teelucksingh S, El-Youssef J, Sohan K, Ramsewak S. Prolonged inadvertent pravastatin use in pregnancy. Reprod Toxicol 2004; 18:299-300.
22. Trakadis Y, Blaser S, Hahn CD, Yoon G. A case report of prenatal exposure to rosuvastatin and telmisartan. Paediatr Child Health 2009; 14:450-452.
23. Yaris F, Yaris E, Kadioglu M, et al. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol 2004; 18:619-621.
24. Seguin J, Samuels P. Fluvastatin exposure during pregnancy. Obstet Gynecol 1999; 93 (5 Pt 2):847.
25. Schachter M. Chemical, pharmacokinetic and pharmacodynamics properties of statins: an update. Fundam Clin Parmacol 2005; 19:117-125.
26. Antonopoulos AS, Margaritis M, Lee R, et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18:1519-1530.
27. Grossera N, Erdmanna K, Hemmerlea A, et al. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1q. Biochem Biophys Res Commun 2004; 325:871-876.
28. The StAmP trial: a proof of principle, double-blind, randomised placebocontrolled, multicentre trial of pravaStatin to Ameliorate early-onset Preeclampsia. Medical Research Council; http://www.controlled-trials.com/ ISRCTN23410175.
29. Pravastatin for the prevention of preeclampsia. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); http://clinicaltrials.gov/show/NCT01717586.